Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer

Innovent Biologics, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track Designation to its TOPO1i anti-CLDN18.2 ADC, for the treatment of advanced unresectable or metastatic pancreatic ductal adenocarcinoma that has relapsed and/or is refractory to one prior line of therapy.